PMC:7212965 / 1223-2222 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T5","span":{"begin":473,"end":478},"obj":"Body_part"},{"id":"T6","span":{"begin":565,"end":572},"obj":"Body_part"},{"id":"T7","span":{"begin":736,"end":741},"obj":"Body_part"},{"id":"T8","span":{"begin":922,"end":927},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma82749"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma7197"}],"text":"We identified 118 studies and used a hierarchal study selection process to identify unique cohorts. We performed a meta-analysis of 47 studies including 10,890 unique patients. Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) and alanine transaminase 15.0% (95% CI, 13.6%–16.4%). When we compared studies from China to studies from other countries in subgroup analyses, diarrhea, nausea/vomiting, and liver abnormalities were more prevalent outside of China, with diarrhea reported in 18.3% (95% CI, 16.6%–20.1%). Isolated GI symptoms were reported rarely. We also summarized the Gl and liver adverse effects of the most commonly utilized medications for COVID-19."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T5","span":{"begin":473,"end":478},"obj":"Body_part"},{"id":"T6","span":{"begin":736,"end":741},"obj":"Body_part"},{"id":"T7","span":{"begin":922,"end":927},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A7","pred":"uberon_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":"We identified 118 studies and used a hierarchal study selection process to identify unique cohorts. We performed a meta-analysis of 47 studies including 10,890 unique patients. Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) and alanine transaminase 15.0% (95% CI, 13.6%–16.4%). When we compared studies from China to studies from other countries in subgroup analyses, diarrhea, nausea/vomiting, and liver abnormalities were more prevalent outside of China, with diarrhea reported in 18.3% (95% CI, 16.6%–20.1%). Isolated GI symptoms were reported rarely. We also summarized the Gl and liver adverse effects of the most commonly utilized medications for COVID-19."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T8","span":{"begin":237,"end":245},"obj":"Disease"},{"id":"T9","span":{"begin":705,"end":713},"obj":"Disease"},{"id":"T10","span":{"begin":799,"end":807},"obj":"Disease"},{"id":"T11","span":{"begin":990,"end":998},"obj":"Disease"}],"attributes":[{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"We identified 118 studies and used a hierarchal study selection process to identify unique cohorts. We performed a meta-analysis of 47 studies including 10,890 unique patients. Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) and alanine transaminase 15.0% (95% CI, 13.6%–16.4%). When we compared studies from China to studies from other countries in subgroup analyses, diarrhea, nausea/vomiting, and liver abnormalities were more prevalent outside of China, with diarrhea reported in 18.3% (95% CI, 16.6%–20.1%). Isolated GI symptoms were reported rarely. We also summarized the Gl and liver adverse effects of the most commonly utilized medications for COVID-19."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T13","span":{"begin":35,"end":36},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T14","span":{"begin":113,"end":114},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T15","span":{"begin":473,"end":478},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T16","span":{"begin":473,"end":478},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T17","span":{"begin":736,"end":741},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T18","span":{"begin":736,"end":741},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T19","span":{"begin":922,"end":927},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T20","span":{"begin":922,"end":927},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"}],"text":"We identified 118 studies and used a hierarchal study selection process to identify unique cohorts. We performed a meta-analysis of 47 studies including 10,890 unique patients. Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) and alanine transaminase 15.0% (95% CI, 13.6%–16.4%). When we compared studies from China to studies from other countries in subgroup analyses, diarrhea, nausea/vomiting, and liver abnormalities were more prevalent outside of China, with diarrhea reported in 18.3% (95% CI, 16.6%–20.1%). Isolated GI symptoms were reported rarely. We also summarized the Gl and liver adverse effects of the most commonly utilized medications for COVID-19."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3","span":{"begin":208,"end":210},"obj":"Chemical"},{"id":"T4","span":{"begin":510,"end":519},"obj":"Chemical"},{"id":"T7","span":{"begin":565,"end":572},"obj":"Chemical"},{"id":"T8","span":{"begin":858,"end":860},"obj":"Chemical"}],"attributes":[{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_73907"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_132943"},{"id":"A5","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_29995"},{"id":"A6","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_72314"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_16449"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_73907"}],"text":"We identified 118 studies and used a hierarchal study selection process to identify unique cohorts. We performed a meta-analysis of 47 studies including 10,890 unique patients. Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) and alanine transaminase 15.0% (95% CI, 13.6%–16.4%). When we compared studies from China to studies from other countries in subgroup analyses, diarrhea, nausea/vomiting, and liver abnormalities were more prevalent outside of China, with diarrhea reported in 18.3% (95% CI, 16.6%–20.1%). Isolated GI symptoms were reported rarely. We also summarized the Gl and liver adverse effects of the most commonly utilized medications for COVID-19."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T7","span":{"begin":237,"end":245},"obj":"Phenotype"},{"id":"T8","span":{"begin":294,"end":309},"obj":"Phenotype"},{"id":"T9","span":{"begin":340,"end":354},"obj":"Phenotype"},{"id":"T10","span":{"begin":473,"end":492},"obj":"Phenotype"},{"id":"T11","span":{"begin":705,"end":713},"obj":"Phenotype"},{"id":"T12","span":{"begin":715,"end":730},"obj":"Phenotype"},{"id":"T13","span":{"begin":736,"end":755},"obj":"Phenotype"},{"id":"T14","span":{"begin":799,"end":807},"obj":"Phenotype"}],"attributes":[{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0002017"},{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0002027"},{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0001392"},{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0002017"},{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0001392"},{"id":"A14","pred":"hp_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/HP_0002014"}],"text":"We identified 118 studies and used a hierarchal study selection process to identify unique cohorts. We performed a meta-analysis of 47 studies including 10,890 unique patients. Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) and alanine transaminase 15.0% (95% CI, 13.6%–16.4%). When we compared studies from China to studies from other countries in subgroup analyses, diarrhea, nausea/vomiting, and liver abnormalities were more prevalent outside of China, with diarrhea reported in 18.3% (95% CI, 16.6%–20.1%). Isolated GI symptoms were reported rarely. We also summarized the Gl and liver adverse effects of the most commonly utilized medications for COVID-19."}

{"project":"LitCovid-sentences","denotations":[{"id":"T10","span":{"begin":0,"end":99},"obj":"Sentence"},{"id":"T11","span":{"begin":100,"end":176},"obj":"Sentence"},{"id":"T12","span":{"begin":177,"end":380},"obj":"Sentence"},{"id":"T13","span":{"begin":381,"end":428},"obj":"Sentence"},{"id":"T14","span":{"begin":429,"end":614},"obj":"Sentence"},{"id":"T15","span":{"begin":615,"end":848},"obj":"Sentence"},{"id":"T16","span":{"begin":849,"end":891},"obj":"Sentence"},{"id":"T17","span":{"begin":892,"end":999},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"We identified 118 studies and used a hierarchal study selection process to identify unique cohorts. We performed a meta-analysis of 47 studies including 10,890 unique patients. Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) and alanine transaminase 15.0% (95% CI, 13.6%–16.4%). When we compared studies from China to studies from other countries in subgroup analyses, diarrhea, nausea/vomiting, and liver abnormalities were more prevalent outside of China, with diarrhea reported in 18.3% (95% CI, 16.6%–20.1%). Isolated GI symptoms were reported rarely. We also summarized the Gl and liver adverse effects of the most commonly utilized medications for COVID-19."}

{"project":"LitCovid-PubTator","denotations":[{"id":"53","span":{"begin":858,"end":860},"obj":"Gene"},{"id":"54","span":{"begin":208,"end":210},"obj":"Gene"},{"id":"55","span":{"begin":167,"end":175},"obj":"Species"},{"id":"56","span":{"begin":419,"end":427},"obj":"Species"},{"id":"57","span":{"begin":237,"end":245},"obj":"Disease"},{"id":"58","span":{"begin":294,"end":300},"obj":"Disease"},{"id":"59","span":{"begin":301,"end":309},"obj":"Disease"},{"id":"60","span":{"begin":340,"end":354},"obj":"Disease"},{"id":"61","span":{"begin":464,"end":492},"obj":"Disease"},{"id":"62","span":{"begin":705,"end":713},"obj":"Disease"},{"id":"63","span":{"begin":715,"end":721},"obj":"Disease"},{"id":"64","span":{"begin":722,"end":730},"obj":"Disease"},{"id":"65","span":{"begin":736,"end":755},"obj":"Disease"},{"id":"66","span":{"begin":799,"end":807},"obj":"Disease"},{"id":"67","span":{"begin":990,"end":998},"obj":"Disease"}],"attributes":[{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"Gene:2770"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"Gene:2770"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"Tax:9606"},{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"Tax:9606"},{"id":"A57","pred":"tao:has_database_id","subj":"57","obj":"MESH:D003967"},{"id":"A58","pred":"tao:has_database_id","subj":"58","obj":"MESH:D009325"},{"id":"A59","pred":"tao:has_database_id","subj":"59","obj":"MESH:D014839"},{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"MESH:D015746"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"MESH:D006973"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"MESH:D003967"},{"id":"A63","pred":"tao:has_database_id","subj":"63","obj":"MESH:D009325"},{"id":"A64","pred":"tao:has_database_id","subj":"64","obj":"MESH:D014839"},{"id":"A65","pred":"tao:has_database_id","subj":"65","obj":"MESH:D008107"},{"id":"A66","pred":"tao:has_database_id","subj":"66","obj":"MESH:D003967"},{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"We identified 118 studies and used a hierarchal study selection process to identify unique cohorts. We performed a meta-analysis of 47 studies including 10,890 unique patients. Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) and alanine transaminase 15.0% (95% CI, 13.6%–16.4%). When we compared studies from China to studies from other countries in subgroup analyses, diarrhea, nausea/vomiting, and liver abnormalities were more prevalent outside of China, with diarrhea reported in 18.3% (95% CI, 16.6%–20.1%). Isolated GI symptoms were reported rarely. We also summarized the Gl and liver adverse effects of the most commonly utilized medications for COVID-19."}